Thelansis

 Rosacea, a prevalent chronic inflammatory condition, is characterized by recurrent flushing, erythema, telangiectasia, and papules or pustules typically on the nose, chin, cheeks, and forehead. It encompasses four clinical subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular; though these categories may overlap, patients often exhibit features from multiple subtypes that can change over time. Eye involvement occurs in 50 to 75 percent of rosacea cases, with symptoms ranging from dryness, redness, and tearing to sensations of tingling or burning, light sensitivity, and blurred vision. Beyond physical symptoms, rosacea can also induce psychological distress, including anxiety, embarrassment, and depression, significantly impacting patients' quality of life. The exact cause of rosacea remains elusive, although various factors contribute to its development, including genetics, immune reactions, microorganisms, environmental influences, and neurovascular dysregulat...

 Rosacea is a long-lasting (chronic) skin disease that affects the face, primarily the forehead, cheeks, nose, and chin. Rosacea signs and symptoms vary and may come and go or change over time. Several genes in a family known as the human leukocyte antigen (HLA) complex are thought to play roles in rosacea. ·        Rosacea prevalence range from less than 1 per cent to more than 20 per cent of the population. Thelansis’s “Rosacea Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rosacea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Rosacea across 8 MM market from the centre of Exc...